---
schema_version: "secwatch.filing_event.v1"
accession: "0000719135-23-000025"
form_type: "8-K"
ticker: "APYX"
cik: "0000719135"
company_name: "Apyx Medical Corp"
filed_at: "2023-05-11T23:59:59+00:00"
generated_at: "2026-06-15T05:11:54.938111+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Apyx Medical Q1 revenue $12.1M (-3% YoY); raises FY2023 guidance; FDA updates Safety Communication

## Summary
- Total revenue $12.1M (-3% YoY); Advanced Energy $9.7M (-10%); OEM $2.5M (+46%).
- Net loss $3.5M ($0.10/share) improved from $5.9M loss in Q1 2022; Adjusted EBITDA loss $4.0M.
- Raises FY2023 total revenue guidance to $59-62M (prior $58-61M); Advanced Energy $51-54M; net loss expected ~$10.5M.
- FDA updated Safety Communication on May 10 clearing Renuvion APR handpiece for subcutaneous soft tissue coagulation post-liposuction.
- Closed sale-leaseback of Clearwater facility for $6.6M net cash; secured $35M credit facility with MidCap.

## SEC filing metadata
- accession: 0000719135-23-000025
- form_type: 8-K
- ticker: APYX
- cik: 0000719135
- company_name: Apyx Medical Corp
- filed_at: 2023-05-11T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/719135/000071913523000025/0000719135-23-000025-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/719135/000071913523000025/apyx-20230511.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000719135-23-000025
- JSON: https://secwatch.observer/filing/0000719135-23-000025.json
- Plain text: https://secwatch.observer/filing/0000719135-23-000025.txt

## Key facts
- Earnings Releases
  Apyx Medical Corp reported the first quarter ended March 31, 2023 results: revenue $12.1 million, net income Net loss attributable to stockholders of $3.5 million. Guidance raised.
  - Period: the first quarter ended March 31, 2023
  - Revenue: $12.1 million
  - Net income: Net loss attributable to stockholders of $3.5 million
  - Guidance: raised
  - Result: reported results
  source text: its first quarter ended March 31, 2023, and updated financial expectations for the full year ending December 31, 2023. First Quarter 2023 Financial Summary : • Total revenue of $12.1 million, down 3% year-over-year. ◦ Advanced Energy revenue of $9.7 million, down 10% year-over-year. ◦ OEM revenue of $2.5 million, up 46% year-over-year. • Net loss attributable to
  evidence_url: https://www.sec.gov/Archives/edgar/data/719135/000071913523000025/0000719135-23-000025-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.